TENDCART

For patients trapped in cycles of escalating analgesic use, TENDCART's regenerative mechanism offers a credible exit pathway — restoring tissue integrity and eliminating the structural pain source rather than suppressing the pain signal alone.

Tissue regeneration reduces the structural pain generators (cartilage erosion, tendon micro-tears) that drive persistent nociceptor activation in chronic musculoskeletal pain. Early data suggests pain reduction scores continue to improve after the acute treatment phase, consistent with the progressive nature of tissue repair rather than symptom suppression. Potential to break the chronification cycle of structural damage → inflammation → sensitisation → further damage that characterises progressive joint and tendon pain disorders. Anti-inflammatory bioactive components concurrently suppress the inflammatory mediators responsible for peripheral sensitisation and central pain amplification.

Chronic knee pain from cartilage defects, refractory Achilles tendinopathy, and persistent patellar tendon pain are the primary pain indications in the TENDCART Phase III programme. Pain outcomes assessed using NRS, KOOS, VISA-A, and PROMIS Pain Interference scales to comprehensively characterise the analgesic benefit profile across indications. Combination with structured pain rehabilitation programmes is planned in trial arms to evaluate the additive benefit of TENDCART within multimodal pain pathways. Pain management specialists and rheumatologists interested in the TENDCART early access programme should contact the medical affairs team for eligibility information.